Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma

Xiaojing Du(Sun Yat-sen University), Gaoyuan Wang(Sun Yat-sen University), Xiao‐Dong Zhu(Guangxi Medical University), Yaqian Han(Central South University), Lei Feng(Zhongshan People's Hospital), Liangfang Shen(Central South University), Kunyu Yang(Union Hospital), Lei Chen(Sun Yat-sen University), Yan‐Ping Mao(Sun Yat-sen University), Ling‐Long Tang(Sun Yat-sen University), Ling Li(Guangxi Medical University), Zheng Wu(Central South University), Guiqiong Xu(Zhongshan People's Hospital), Qin Zhou(Central South University), Jing Huang(Union Hospital), Rui Guo(Sun Yat-sen University), Yuan Zhang(Sun Yat-sen University), Xu Liu(Sun Yat-sen University), Guan‐Qun Zhou(Sun Yat-sen University), Wen‐Fei Li(Sun Yat-sen University), Cheng Xu(Sun Yat-sen University), Lin Li(Sun Yat-sen University), Yu‐Pei Chen(Sun Yat-sen University), Fo‐Ping Chen(Sun Yat-sen University), Xiaoyu Liang(Central South University), Siyuan Chen(Sun Yat-sen University), Shuqi Li(Sun Yat-sen University), Chunyan Cui(Sun Yat-sen University), Jibin Li(Sun Yat-sen University), Jian Ren(Sun Yat-sen University), Ming‐Yuan Chen(Sun Yat-sen University), Lizhi Liu(Sun Yat-sen University), Ying Sun(Sun Yat-sen University), Jun Ma(Sun Yat-sen University)
Cancer Cell
January 18, 2024
Cited by 62Open Access
Full Text

Abstract

The AJCC/UICC TNM classification describes anatomic extent of tumor progression and guides treatment decisions. Our comprehensive analysis of 8,834 newly diagnosed patients with non-metastatic Epstein-Barr virus related nasopharyngeal carcinoma (NPC) from six Chinese centers indicates certain limitations in the current staging system. The 8th edition of the AJCC/UICC TNM classification inadequately differentiates patient outcomes, particularly between T2 and T3 categories and within the N classification. We propose reclassifying cases of T3 NPC with early skull-base invasion as T2, and elevating N1-N2 cases with grade 3 image-identified extranodal extension (ENE) to N3. Additionally, we suggest combining T2N0 with T1N0 into a single stage IA. For de novo metastatic (M1) NPC, we propose subdivisions of M1a, defined by 1-3 metastatic lesions without liver involvement, and M1b, characterized by >3 metastatic lesions or liver involvement. This proposal better reflects responses of NPC patients to the up-to-date treatments and their evolving risk profiles.


Related Papers

No related papers found

Powered by citation graph analysis